SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL EBITDA Margin

EBITDA as a percentage of revenue.

SNDL Inc.NASDAQ: SNDL

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 1.4%

EBITDA Margin was 1.4% in Q1 FY2026, up 0.7 pp from a year earlier. On a trailing-twelve-month basis it was 5.3%, up 10.5 pp year over year. Over 3 fiscal years it widened by 50.9 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -1.5% for the fiscal year ending Dec 2026, down from 5.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
1.4%-8.7 pp QoQ
Last fiscal yearDec 2025
5.1%+9.5 pp YoY
LTMMar 2026
5.3%+10.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.7 pp-1.3 pp-2.1 pp
1 year+9.5 pp-6.6 pp-16.2 pp
3 years+50.9 pp+1.7 pp-49.2 pp
5 years+5.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
5.1%
Year-over-year change
+9.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How SNDL compares with its peers on the latest reported figures

  • SNDL's LTM Mar 2026 EBITDA Margin of 5.3% is the 5th highest of the 8 companies compared; the peer median is 7.3%.
  • Its year-over-year change of +10.5 pp is the 2nd highest of 8, against a peer median of +6.2 pp.
  • Over three fiscal years its change of +50.9 pp compares with a peer median of +8.2 pp.
SNDL Competitors Peer median
EBITDA Margin for SNDL and competitors
Company Period LTM level YoY 3-year change
SIGASIGA Technologies, Inc.LTM Mar 202629.3% -22.9 pp-7.6 pp
EBSEmergent BioSolutions Inc.LTM Mar 202622.8% +10.3 pp+31.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 20269.5% +43.6 pp+249.5 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 20267.3% +8.1 pp+4.2 pp
SNDLSNDL Inc.LTM Mar 20265.3% +10.5 pp+50.9 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-2.5% -5.1 pp+8.2 pp
EOLSEvolus, Inc.LTM Mar 2026-4.6% +6.2 pp+28.7 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-102.7% -35.0 pp-65.4 pp
CMPSCOMPASS Pathways plcFY2025— ——
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding SNDL) 7.3%+6.2 pp+8.2 pp

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.